Aim-quoted Omega has reported an adjusted pre-tax loss of £400,000 in the year to 31 March, up from a loss of £300,000 in the prior 12 months, while core earnings from continuing operations increased to £890,000 from £200,000. Like-for-like revenue of continuing operations increased by 12 per cent to £9.82 million, while the firm also noted previously flagged exceptional charges of £7.7m related to stopping its allergy development activities.
William Rhodes, interim non-executive chairman of Alva-based Omega, said: “We believe that our outlook for the coming fiscal year is excellent – while we have decided to stop development of the allergen product lines… we are rapidly developing new tests, together with our partners, for Covid-19 that will need to be made and sold, ultimately, in the hundreds of thousands of units, if not millions.”
The firm also offers Visitect, which tests the immune systems of HIV patients. Rhodes said: “We see our Visitec product lines once again growing significantly as the world balances Covid-19 with the need to test patients with other life-threatening, and in some cases chronic, diseases such as HIV.”
He added that Omega has been key in developing and making “much-needed” Covid-19 tests for use globally, and “to also be able to serve the needs of the people of the UK and Scotland”.
Analysts at FinnCap said they expect “strong” growth and a profitable current financial year for Omega.
A message from the Editor:
Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.
The dramatic events of 2020 are having a major impact on many of our advertisers - and consequently the revenue we receive. We are now more reliant than ever on you taking out a digital subscription to support our journalism.
Subscribe to scotsman.com and enjoy unlimited access to Scottish news and information online and on our app. Visit https://www.scotsman.com/subscriptions now to sign up. By supporting us, we are able to support you in providing trusted, fact-checked content for this website.